Kathryn Rough1, George R Seage1, Paige L Williams1, Sonia Hernandez-Diaz1, Yanling Huo1, Ellen G Chadwick1, Judith S Currier1, Risa M Hoffman1, Emily Barr1, David E Shapiro1, Kunjal Patel1. 1. From the Departments of Epidemiology (K.R., G.R.S., P.L.W., S.H.-D., K.P.) and Biostatistics (P.L.W., D.E.S.) and the Center for Biostatistics and AIDS Research (Y.H., D.E.S., K.P.), Harvard T.H. Chan School of Public Health, and the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School (K.R.), Boston; the Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago (E.G.C.); the Department of Medicine and Division of Infectious Diseases, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J.S.C., R.M.H.); and the Department of Pediatrics, University of Colorado School of Medicine, Aurora (E.B.).
Abstract
BACKGROUND: In a previous trial of antiretroviral therapy (ART) involving pregnant women with human immunodeficiency virus (HIV) infection, those randomly assigned to receive tenofovir, emtricitabine, and ritonavir-boosted lopinavir (TDF-FTC-LPV/r) had infants at greater risk for very premature birth and death within 14 days after delivery than those assigned to receive zidovudine, lamivudine, and ritonavir-boosted lopinavir (ZDV-3TC-LPV/r). METHODS: Using data from two U.S.-based cohort studies, we compared the risk of adverse birth outcomes among infants with in utero exposure to ZDV-3TC-LPV/r, TDF-FTC-LPV/r, orTDF-FTC with ritonavir-boosted atazanavir (ATV/r). We evaluated the risk of preterm birth (<37 completed weeks of gestation), very preterm birth (<34 completed weeks), low birth weight (<2500 g), and very low birth weight (<1500 g). Risk ratios with 95% confidence intervals were estimated with the use of modified Poisson models to adjust for confounding. RESULTS: There were 4646 birth outcomes. Few infants or fetuses were exposed to TDF-FTC-LPV/r (128 [2.8%]) as the initial ART regimen during gestation, in contrast with TDF-FTC-ATV/r (539 [11.6%]) and ZDV-3TC-LPV/r (954 [20.5%]). As compared with women receiving ZDV-3TC-LPV/r, women receiving TDF-FTC-LPV/r had a similar risk of preterm birth (risk ratio, 0.90; 95% confidence interval [CI], 0.60 to 1.33) and low birth weight (risk ratio, 1.13; 95% CI, 0.78 to 1.64). As compared to women receiving TDF-FTC-ATV/r, women receiving TDF-FTC-LPV/r had a similar or slightly higher risk of preterm birth (risk ratio, 1.14; 95% CI, 0.75 to 1.72) and low birth weight (risk ratio, 1.45; 95% CI, 0.96 to 2.17). There were no significant differences between regimens in the risk of very preterm birth or very low birth weight. CONCLUSIONS: The risk of adverse birth outcomes was not higher with TDF-FTC-LPV/r than with ZDV-3TC-LPV/r or TDF-FTC-ATV/r among HIV-infected women and their infants in the United States, although power was limited for some comparisons. (Funded by the National Institutes of Health and others.).
RCT Entities:
BACKGROUND: In a previous trial of antiretroviral therapy (ART) involving pregnant women with human immunodeficiency virus (HIV) infection, those randomly assigned to receive tenofovir, emtricitabine, and ritonavir-boosted lopinavir (TDF-FTC-LPV/r) had infants at greater risk for very premature birth and death within 14 days after delivery than those assigned to receive zidovudine, lamivudine, and ritonavir-boosted lopinavir (ZDV-3TC-LPV/r). METHODS: Using data from two U.S.-based cohort studies, we compared the risk of adverse birth outcomes among infants with in utero exposure to ZDV-3TC-LPV/r, TDF-FTC-LPV/r, or TDF-FTC with ritonavir-boosted atazanavir (ATV/r). We evaluated the risk of preterm birth (<37 completed weeks of gestation), very preterm birth (<34 completed weeks), low birth weight (<2500 g), and very low birth weight (<1500 g). Risk ratios with 95% confidence intervals were estimated with the use of modified Poisson models to adjust for confounding. RESULTS: There were 4646 birth outcomes. Few infants or fetuses were exposed to TDF-FTC-LPV/r (128 [2.8%]) as the initial ART regimen during gestation, in contrast with TDF-FTC-ATV/r (539 [11.6%]) and ZDV-3TC-LPV/r (954 [20.5%]). As compared with women receiving ZDV-3TC-LPV/r, women receiving TDF-FTC-LPV/r had a similar risk of preterm birth (risk ratio, 0.90; 95% confidence interval [CI], 0.60 to 1.33) and low birth weight (risk ratio, 1.13; 95% CI, 0.78 to 1.64). As compared to women receiving TDF-FTC-ATV/r, women receiving TDF-FTC-LPV/r had a similar or slightly higher risk of preterm birth (risk ratio, 1.14; 95% CI, 0.75 to 1.72) and low birth weight (risk ratio, 1.45; 95% CI, 0.96 to 2.17). There were no significant differences between regimens in the risk of very preterm birth or very low birth weight. CONCLUSIONS: The risk of adverse birth outcomes was not higher with TDF-FTC-LPV/r than with ZDV-3TC-LPV/r or TDF-FTC-ATV/r among HIV-infectedwomen and their infants in the United States, although power was limited for some comparisons. (Funded by the National Institutes of Health and others.).
Authors: Susan B Brogly; Mark J Abzug; D Heather Watts; Coleen K Cunningham; Paige L Williams; James Oleske; Daniel Conway; Rhoda S Sperling; Hans Spiegel; Russell B Van Dyke Journal: Pediatr Infect Dis J Date: 2010-08 Impact factor: 2.129
Authors: Alice M Stek; Mark Mirochnick; Edmund Capparelli; Brookie M Best; Chengcheng Hu; Sandra K Burchett; Carol Elgie; Diane T Holland; Elizabeth Smith; Ruth Tuomala; Amanda Cotter; Jennifer S Read Journal: AIDS Date: 2006-10-03 Impact factor: 4.177
Authors: Kunjal Patel; David E Shapiro; Susan B Brogly; Elizabeth G Livingston; Alice M Stek; Arlene D Bardeguez; Ruth E Tuomala Journal: J Infect Dis Date: 2010-04-01 Impact factor: 5.226
Authors: Mary G Fowler; Min Qin; Susan A Fiscus; Judith S Currier; Patricia M Flynn; Tsungai Chipato; James McIntyre; Devasena Gnanashanmugam; George K Siberry; Anne S Coletti; Taha E Taha; Karin L Klingman; Francis E Martinson; Maxensia Owor; Avy Violari; Dhayendre Moodley; Gerhard B Theron; Ramesh Bhosale; Raziya Bobat; Benjamin H Chi; Renate Strehlau; Pendo Mlay; Amy J Loftis; Renee Browning; Terence Fenton; Lynette Purdue; Michael Basar; David E Shapiro; Lynne M Mofenson Journal: N Engl J Med Date: 2016-11-03 Impact factor: 91.245
Authors: Paige L Williams; George R Seage; Russell B Van Dyke; George K Siberry; Raymond Griner; Katherine Tassiopoulos; Cenk Yildirim; Jennifer S Read; Yanling Huo; Rohan Hazra; Denise L Jacobson; Lynne M Mofenson; Kenneth Rich Journal: Am J Epidemiol Date: 2012-04-06 Impact factor: 4.897
Authors: Brookie M Best; Alice M Stek; Mark Mirochnick; Chengcheng Hu; Hong Li; Sandra K Burchett; Steven S Rossi; Elizabeth Smith; Jennifer S Read; Edmund V Capparelli Journal: J Acquir Immune Defic Syndr Date: 2010-08 Impact factor: 3.731
Authors: Astrid-Jane Greenup; Pok Kern Tan; Vi Nguyen; Anne Glass; Scott Davison; Ushmi Chatterjee; Susan Holdaway; Dev Samarasinghe; Kathy Jackson; Stephen A Locarnini; Miriam T Levy Journal: J Hepatol Date: 2014-05-05 Impact factor: 25.083
Authors: Murli U Purswani; Kunjal Patel; Cheryl A Winkler; Stephen A Spector; Rohan Hazra; George R Seage; Lynne Mofenson; Brad Karalius; Gwendolyn B Scott; Russell B Van Dyke; Jeffrey B Kopp Journal: J Acquir Immune Defic Syndr Date: 2016-09-01 Impact factor: 3.731
Authors: Kartik K Venkatesh; Andrew Edmonds; Daniel Westreich; Jodie Dionne-Odom; Deborah Jones Weiss; Anandi N Sheth; Helen Cejtin; Dominika Seidman; Seble Kassaye; Howard Minkoff; Jessica Atrio; Lisa Rahangdale; Adaora A Adimora Journal: HIV Med Date: 2021-09-12 Impact factor: 3.094
Authors: Jim Aizire; Kristina M Brooks; Mark Mirochnick; Patricia M Flynn; Kevin Butler; Jennifer J Kiser; George K Siberry; Terry Fenton; Mae Cababasay; Mary G Fowler Journal: J Acquir Immune Defic Syndr Date: 2020-02-01 Impact factor: 3.771
Authors: Maria L Alcaide; Violeta J Rodriguez; John M Abbamonte; Shandir Ramlagan; Sibusiso Sifunda; Stephen M Weiss; Karl Peltzer; Deborah L Jones Journal: Open Forum Infect Dis Date: 2019-10-09 Impact factor: 3.835
Authors: Virginia Rasi; Helen Peters; Rebecca Sconza; Kate Francis; Laurette Bukasa; Claire Thorne; Mario Cortina-Borja Journal: HIV Med Date: 2022-02-18 Impact factor: 3.094
Authors: Jesse F Mangold; Ria Goswami; Ashley N Nelson; David R Martinez; Genevieve G Fouda; Sallie R Permar Journal: Pediatr Infect Dis J Date: 2021-05-01 Impact factor: 3.806
Authors: Jodie Dionne-Odom; Michelle J Khan; Victoria C Jauk; Jeff Szychowski; Dustin M Long; Suzanne Wallace; Cherry Neely; Karen Fry; Jeanne Marrazzo; Marilyn Crain; Alan T N Tita Journal: Infect Dis Obstet Gynecol Date: 2019-04-01